HC Wainwright Reaffirms “Buy” Rating for Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They currently have a $158.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 112.00% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. JPMorgan Chase & Co. began coverage on Dianthus Therapeutics in a research report on Friday, September 11th. They issued an “overweight” rating and a $135.00 target price on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Friday, July 17th. Citigroup began coverage on Dianthus Therapeutics in a research report on Friday, September 4th. They set a “buy” rating and a $156.00 price objective on the stock. Truist Financial lifted their price objective on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $131.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $129.83.

Dianthus Therapeutics Stock Down 0.3%

Shares of NASDAQ DNTH traded down $0.23 during mid-day trading on Thursday, reaching $74.53. 943,569 shares of the company were exchanged, compared to its average volume of 929,135. Dianthus Therapeutics has a 1 year low of $32.22 and a 1 year high of $117.88. The stock has a market cap of $4.08 billion, a price-to-earnings ratio of -17.96 and a beta of 1.35. The firm has a 50-day moving average of $100.75 and a 200 day moving average of $94.49.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.30 million. On average, equities analysts forecast that Dianthus Therapeutics will post -3.81 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 23,124 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. This represents a 85.25% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Adam Veness sold 16,167 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 242,429 shares of company stock worth $26,118,913. Insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in Dianthus Therapeutics during the second quarter worth $401,990,000. Wellington Management Group LLP grew its holdings in Dianthus Therapeutics by 24.4% during the 2nd quarter. Wellington Management Group LLP now owns 3,229,882 shares of the company’s stock valued at $314,849,000 after buying an additional 634,099 shares during the last quarter. ABS Investment Management LLC acquired a new stake in Dianthus Therapeutics during the 2nd quarter valued at $194,960,000. Assenagon Asset Management S.A. grew its holdings in Dianthus Therapeutics by 160.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after buying an additional 451,597 shares during the last quarter. Finally, Jennison Associates LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at $40,713,000. 47.53% of the stock is owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.